SCHEMBL8934537

SCHEMBL8934537

COC(=O)C(C)(C)CCCOc1ccc2ccc(=O)oc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 10/20 0.62
CA9 Q16790 9/20 0.62
CA1 P00915 7/20 0.62
CA7 P43166 5/20 0.62
CA6 P23280 4/20 0.62
CA14 Q9ULX7 4/20 0.62
CA4 P22748 4/20 0.62
CA5B Q9Y2D0 3/20 0.62
CA2 P00918 2/20 0.62
CA3 P07451 2/20 0.62
CA5A P35218 3/20 0.59
CYP1A2 P05177 1/20 0.54
MAOA P21397 5/20 0.54
MAOB P27338 5/20 0.54
KDM4E B2RXH2 6/20 0.53
ALDH1A1 P00352 5/20 0.53
HPGD P15428 3/20 0.53
HSD17B10 Q99714 3/20 0.53
TP53 P04637 1/20 0.53
POLB P06746 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10459353 0.97 CA12 (0.58) CA12CA9CA1CA7CA6
SCHEMBL8934524 0.88 CA12 (0.65) CA12CA9CA1CA7CA6
SCHEMBL8934483 0.83 AR (0.61) MAOAMAOBKDM4EALDH1A1HPGD
SCHEMBL17299895 0.81 CA12 (0.53) CA12CA9CA1CA7CA6
SCHEMBL14356146 0.80 CA12 (0.64) CA12CA9CA1CA7CA6
SCHEMBL23227094 0.79 CA12 (0.71) CA12CA9CA1CA7CA6
SCHEMBL2482990 0.79 CA12 (0.61) CA12CA9CA1CA7CA6
SCHEMBL13670111 0.79 CA12 (0.62) CA12CA9CA1CA7CA6
SCHEMBL31086715 0.78 CA12 (0.65) CA12CA9CA1CA7CA6
7-Butoxycoumarin SCHEMBL6686295 0.78 CA12 (1.00) CA12CA9CA1CA7CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 WO claimed
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 WO disclosed